Homepage Top Section2

The financing round, which brings the total funds raised by the firm to $143.5m, was led by EQT Life Sciences, investing from Droia Ventures, Sanofi Ventures and the

F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US.

Under the agreement terms, Volastra receives an exclusive global license (ex-China) for the development and commercialisation of sovilnesib. Amgen will, in exchange, receive an upfront mix of cash

RAG-17 has been designed to act on and knockdown SOD1 expression in patients with pathogenic mutations that are known to cause ALS. The chemistry of the therapeutic is

Designed to modify SBMA through several mechanisms, AJ201 is currently in a Phase Ib/IIa study in the US to treat spinal and bulbar muscular atrophy (SBMA), which is

Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to

In September last year, Stimufend received approval from the US Food and Drug Administration (FDA) to be used in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs that

TAKHZYRO is a completely human monoclonal antibody that particularly binds and reduces plasma kallikrein activity.   Before this approval, the only approved routine prophylaxis treatment options for children

The European Commission (EC) will now review the recommendation. On receiving approval, this would represent the third authorised indication for the therapy in the EU. Approved in the